Twitter Twitter Facebook Facebook Linked In Linked In Zone In Zone In Google Plus Zone In
 
eNews

Research Update

Bypassing Molecular Evolution by Targeting Toll-like Receptors

Vaccines and immunotherapies utilize the host’s immune system to provide protection against a particular pathogen or disease. While various approaches exist, there are common hurdles that all immune-based approaches must overcome. Primarily, they must elicit an “appropriate” immune response through an antigen containing a cognate sequence to the pathogen. This task can be particularly challenging for pathogens that are prone to mutate. One solution is to target the host’s innate immune system to boost its response to invading pathogens. This method has the additional benefit of limiting the ability of a strain to become resistant to treatment. In a recent paper published in Frontiers in Pharmacology, Alfaro et al. describe a promising safety profile of an aerosolized oligonucleotide and peptide treatment against pneumonia by targeting Toll-like Receptors (TLR).

Read More

 

Giving Back
Thank you for helping us raise almost $3000 for the Leukemia & Lymphoma Society last month!

Sample Offer
Improve RT-PCR specificity with CleanAmp™ One-Step RT-PCR Master Mix. Request your free sample today!

News
InVentis to distribute TriLink products in India
 
A Fast, Cost-Effective Approach to Therapeutic GMP Manufacturing

We've combined our nucleic acid modification expertise with a state-of-the-art facility to now offer therapeutic GMP manufacturing. With a wide variety of available synthesis scales, you can get just the amount of material you need for IND-enabling tox studies and early phase clinical trials. We can deliver your therapeutic oligo, mRNA or nucleotide quickly and at an affordable price regardless of the scale.


State-of-the-Art Facility

Our new GMP facility is dedicated to manufacturing therapeutic products. The controlled labs feature:

  • Validated ISO Class 7 and Class 8 clean rooms
  • Compliance with ICH Q7, CFR 210 and other phase-appropriate guidelines
  • Single pass, HEPA filtered air system
  • Routine monitoring of temperature, pressure, humidity and particle count
  • Fully gowned staff
  • Validated (IQ/OQ) processes, equipment and computer systems
Learn More
Request a Consultation
 
Blog Post

Reflections on Advances in Medicinal Oligonucleotides

  • Oligos Are Not “Magic Bullets”
  • Oligos Have, Nevertheless, Enabled New Drug Paradigms
  • Oligos Continue to Attract Significant Corporate Investments

Oligos didn’t quite prove to be the new paradigm for a speedy concept-to-clinic solution.

Read More

  
 
Your Aptamer Reagent Partner

Let our expertise in modified nucleic acid chemistry and commitment to manufacturing the highest quality reagents support you as you advance aptamer research.

Stocked Random Libraries
Modified Nucleoside Triphosphates
Aptamer Synthesis & Conjugation

Blog Post

Hot Topic in Oligonucleotide Therapeutics: Nanomedicine
  • What is it?
  • Why is it Hot?
  • How do Nucleic Acids Fit in?

Nanomedicine, like almost everything these days, has a wiki site; however, it simply defines nanomedicine as “the medical application of nanotechnology,” which begs questions of what’s nanotechnology and what are some of these applications?

Read More

 

© 2014 TriLink BioTechnologies, Inc. | All Rights Reserved